Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.49 |
| ▸ | CTSS | P25774 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 7/20 | 0.46 |
| ▸ | PPARG | P37231 | 6/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21409086 | 1.00 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL9753568 | 1.00 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| Benzene SCHEMBL28185134 | 0.97 | PPARA (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL4981797 | 0.92 | CTSK (0.52) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL4981804 | 0.92 | CTSK (0.52) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL7430204 | 0.92 | CTSK (0.52) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL1669007 | 0.89 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL1669009 | 0.89 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL30788958 | 0.86 | CTSK (0.46) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL6745774 | 0.86 | CTSK (0.56) | CTSKCTSSMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133078-A1 | VIRAL PROTEASE INHIBITORS WITH A HYDROXYBENZYL ALCOHOL WARHEAD | STICHTING RADBOUD UNIVERSITEIT (NL) | 2025-06-26 | — | — | WO | disclosed |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
| CN-114929705-A | MLL1 inhibitor and anticancer agent | 诺华公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-3773555-A1 | FACTOR XIIA INHIBITORS | University of Leeds (GB) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019186164-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2019-10-03 | — | — | WO | disclosed |
| US-9169295-B2 | Macrocycles and macrocycle stabilized peptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| EP-2627662-B1 | METHODS FOR PREPARING MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20130281657-A1 | MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-24 | — | — | US | disclosed |
| US-8338471-B2 | (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors | MEDIVIR AB (SE) | 2012-12-25 | — | — | US | disclosed |
| US-20120015994-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2012-01-19 | — | — | US | disclosed |
| US-8022092-B2 | (2,5-dioxoimidazolidin-1-yl)-N-hydroxy-acetamides as metalloproteinase inhibitors | MEDIVIR AB (SE) | 2011-09-20 | — | — | US | disclosed |
| US-20090215846-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2009-08-27 | — | — | US | disclosed |
| EP-1757933-A1 | METHOD FOR THE DETERMINATION OF BODY ODOR | Kao Corporation (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281657-A1 | MACROCYCLES AND MACROCYCLE STABILIZED PEPTIDES | PTMS, VIP, MTPN | CTSK 492/4885CTSS 176/4885MEN1 99/4885 |
| US-20120015994-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MMP12, MMP13, MMP14 | CTSK 417/4885CTSS 186/4885MEN1 4708/4885 |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | CTSK 303/4885CTSS 714/4885MEN1 750/4885 |
| US-20090215846-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MMP12, MMP13, MMP14 | CTSK 417/4885CTSS 186/4885MEN1 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.